지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2019.1
- 수록면
- 360 - 365 (6page)
이용수
초록· 키워드
오류제보하기
Despite the high efficacy of direct acting antivirals (DAAs) not all patients successfully clear hepatitis C virus infection, in fact, approximately 1–3% fail to reach a sustained virological response 12 weeks after end of treatment. DAA failures are characterized by advanced liver disease, specific genotypes/subtypes and resistance associated substitutions to the DAA class they have been treated with. Current European Association for the Study of the Liver guidelines recommend three therapeutic options for such patients. The first is a 12 week course of sofosbuvir (SOF), velpatasvir (VEL) and voxilaprevir (VOX), which has shown to be effective in 90–99% of patients and was granted A1 level recommendation. The second option, reserved for patients who have predictors of failure consists in 12 weeks regimen with glecaprevir (GLE) and pibrentasvir (PIB), effective in 90–97%. Finally, although not supported by published data, for especially difficult to treat patients there should theoretically be a benefit in prolonged combinations of SOF+GLE/PIB or SOF/VEL/VOX±ribavirin. This review presents the latest evidence from both clinical trials and real-life on such therapeutic strategies.
목차
등록된 정보가 없습니다.
참고문헌 (21)
참고문헌 신청
Aghemo A / 2013 / New horizons in hepatitis C antiviral therapy with direct-acting antivirals / Hepatology 58:428~438
Pawlotsky JM / 2016 / Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens / Gastroenterology 151:70~86
D’Ambrosio R / 2017 / Direct-acting antivirals : the endgame for hepatitis C / Curr Opin Virol 24:31~37
D’Ambrosio R / 2019 / Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C / J Hepatol 70:379~387
Mettikanont P / 2019 / Systematic review : epidemiology and response to direct-acting antiviral therapy in genotype 6 chronic hepatitis C virus infection / Aliment Pharmacol Ther 49:492~505
Pawlotsky JM / 2016 / Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens / Gastroenterology 151:70~86
D’Ambrosio R / 2017 / Direct-acting antivirals : the endgame for hepatitis C / Curr Opin Virol 24:31~37
D’Ambrosio R / 2019 / Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C / J Hepatol 70:379~387
Mettikanont P / 2019 / Systematic review : epidemiology and response to direct-acting antiviral therapy in genotype 6 chronic hepatitis C virus infection / Aliment Pharmacol Ther 49:492~505
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Real-World Single-Center Experience with Sofosbuvir-Based Regimens for the Treatment of Chronic Hepatitis C Genotype 1 Patients
Gut and Liver
2017 .01
-
Efficacy and safety of sofosbuvir-based regimens for treatment in chronic hepatitis C genotype 1 patients with moderately impaired renal function
Clinical and Molecular Hepatology
2017 .01
-
Real-world Effectiveness and Safety of Direct-acting Antiviral Agents in Patients with Chronic Hepatitis C Genotype 2 Infection: Korean Multicenter Study
Journal of Korean Medical Science
2021 .01
-
Real-Life Effectiveness and Safety of Sofosbuvir-Based Therapy in Genotype 2 Chronic Hepatitis C Patients in South Korea, with Emphasis on the Ribavirin Dose
Gut and Liver
2020 .01
-
High Efficacy and Safety of Flat-Dose Ribavirin Plus Sofosbuvir/Daclatasvir in Genotype 3 Cirrhotic Patients
Gut and Liver
2020 .01
-
Sofosbuvir/velpatasvir plus ribavirin for Child-Pugh B and Child-Pugh C hepatitis C virus-related cirrhosis
Clinical and Molecular Hepatology
2021 .10
-
Efficacy of L-carnitine on ribavirin-induced hemolytic anemia in patients with hepatitis C virus infection
Clinical and Molecular Hepatology
2019 .01
-
Does the old-fashioned sofosbuvir plus ribavirin treatment in genotype 2 chronic hepatitis C patients still works for Koreans?
Clinical and Molecular Hepatology
2018 .01
-
Sofosbuvir-based therapy for patients with chronic hepatitis C: Early experience of its efficacy and safety in Korea
Clinical and Molecular Hepatology
2015 .01
-
Hepatitis C Virus and Antiviral Drug Resistance
Gut and Liver
2016 .01
-
주성분분석을 이용한 C[11]-PIB imaging 영상분석
핵의학기술
2015 .01
-
Efficacy of Direct-Acting Antivirals in Patients with Hepatitis C Virus/Human Immunodeficiency Virus Coinfection: A Gap between Clinical Trial and Real Practice
Gut and Liver
2018 .01
-
Efficacy and safety of ledipasvir/sofosbuvir in 5,028 Mongolian patients infected with genotype 1 hepatitis C virus: A multicenter study
Clinical and Molecular Hepatology
2021 .01
-
Beneficial effects of proximal intestinal bypass reconstruction on glucose metabolism in a type 2 diabetes animal model: a possible reconstruction strategy for diabetic gastric cancer patients
Annals of Surgical Treatment and Research
2021 .04
-
Drug-drug interactions with direct-acting antivirals ? less is more
Clinical and Molecular Hepatology
2021 .01
-
A Program to Treat Hepatitis B in North Korea: A Model of Antiviral Therapy in a Resource-Poor Setting
Gut and Liver
2018 .01
-
Current and future strategies for the treatment of chronic hepatitis C
Clinical and Molecular Hepatology
2021 .01
-
Direct-acting antivirals response in hepatocellular carcinoma: Does the presence of hepatocellular carcinoma matter?
Clinical and Molecular Hepatology
2019 .01
-
Efficacy and safety of sofosbuvir plus ribavirin for Korean patients with hepatitis C virus genotype 2 infection: A retrospective multi-institutional study
Clinical and Molecular Hepatology
2018 .01
-
What is the Long-term Benefit of Direct-acting Antiviral Therapy in Chronic Hepatitis C?
Journal of Korean Medical Science
2019 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0